Lilly’s Retatrutide Cuts HbA1C 1.9% & Weight 15.3%
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly reported that its investigational injectable retatrutide produced significant reductions in blood‑sugar (HbA1C) and weight in a late‑stage study of type‑2 diabetes patients.
- Retatrutide at the highest dose lowered HbA1C by 1.9% after 40 weeks, compared with a 0.8% reduction in the placebo group.
- Retatrutide participants on the highest dose lost 15.3% of body weight, while placebo recipients lost 2.6%.
- Mounjaro showed comparable efficacy to retatrutide in the trial, according to the study.
- Study data include all patients, even those who discontinued treatment.
- Eli Lilly noted that the drug could be especially beneficial for the roughly 60% of type‑2 diabetes adults who are also obese.
Why it matters: Patients with type‑2 diabetes—particularly the estimated 60% who are also obese—could gain a therapy that lowers HbA1C by nearly 2% and drives over 15% body‑weight loss, a magnitude of benefit far exceeding that of most existing diabetes drugs and potentially reshaping treatment options for this high‑risk group.
